Fingerprick autologous blood for dry eyes and persistent epithelial defects

Wawrzynski, James; Mukherjee, H; Moore, Johnny; Smith, J. F.; Reekie, Ian; Patel, Amit; Kumar, B; Illingworth, Christopher D.; Shah, Sunil; Tole, Derek; Sharma, Anant

doi:10.1038/eye.2015.258

Cited by 4 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We compiled a database of journal articles on age-related macular disease (AMD) and Stargardt disease. The latter was chosen to represent the retinal dystrophies because it is the commonest (there are over 100 inherited retinal diseases and we were not resourced to include them all in this study) [ 14 ]. For the sake of brevity we will refer to AMD and Stargardt collectively as macular disease, though as will be seen, the great majority of research articles relates to AMD.…”

Section: Methodsmentioning

confidence: 99%

Macular disease research in the United Kingdom 2011–2014: a bibliometric analysis of outputs, performance and coverage

Royle

Waugh

2015

BMC Res Notes

View full text Add to dashboard Cite

BackgroundBibliometric indicators, based on measuring patterns of publications and citations, are widely used by universities and research funders to assess research performance. Our aims were to: (1) perform a bibliometric analysis of UK macular disease research publications from 2011 to 2014 and compare this with the other countries producing major output in the area, and (2) compare the pattern of UK macular disease publication with the priorities for age-related macular degeneration (AMD) developed by the Sight Loss and Vision Priority Setting Partnership (SLV-PSP).MethodsWe used the Scopus database to retrieve macular disease articles published from 2011 to 2014. Citations to articles from 2011 to 2013 and journal impact factors (JIFs) for 2014 articles were obtained. Articles with UK authors were allocated to the 10 SLV-PSP priorities for age-related macular degeneration (AMD), where possible.ResultsThe UK, USA, and Germany and China were the top four producers of macular disease research from 2011 to 2013. All except China had a higher proportion of citations than articles. There were 421 articles with UK authors published from 2011 to 2014, of which 49 % had international collaborators. The UK produced 9.7 % of the world’s output of macular disease articles from 2011 to 2013, but received 14.2 % of the world’s share of citations. UK authors’ share of the world’s top 10 % of cited publications from 2011 to 2013 was 16.2 %. In 2014, 13.2 % of UK articles were in journals in the top 10 % when ranked by Journal Impact Factors (JIFs), while the overall UK article share for that year was 9.9 %. UK articles did not show a strong correlation between citations and JIFs. The SLV-PSP published a set of 10 priorities for research into age-related macular degeneration in October 2103. Only 8 % of the UK’s 2011–2014 publications matched the SLV-PSP top priority (treatment to stop dry AMD progressing) and 34 % did not match any of the SLV-PSP priorities, mainly because the priorities did not include invasive treatment of wet AMD.ConclusionsThe UK is performing well in macular research, based on bibliometric indicators. The distribution of past research topics does not match the priorities set by the SLV-PSP.

show abstract

Section: Methodsmentioning

confidence: 99%

Macular disease research in the United Kingdom 2011–2014: a bibliometric analysis of outputs, performance and coverage

Royle

Waugh

2015

BMC Res Notes

View full text Add to dashboard Cite

show abstract

“…Allogeneic serum forms are however also increasingly available. Other haemoderivative topical therapies have been proposed: finger-prick autologous blood treatment which uses whole capillary blood obtained from a sterilized fingertip [32]; platelet-rich plasma [33]; and umbilical cord serum.…”

Section: Treatmentmentioning

confidence: 99%

The management of neurotrophic keratitis

Jabbour

Ashton

Balal

et al. 2021

Current Opinion in Ophthalmology

View full text Add to dashboard Cite

Purpose of reviewThe management of neurotrophic keratitis (NK) has evolved in the last decade. The present article reviews updated management guidelines of this entity, as well as future innovations in the field. Recent findingsThe advent of confocal microscopy has allowed for the first time to image corneal nerves. In addition, multiple novel topical treatments such as nerve growth factor have improved the prognosis of this disease, with many other in the pipeline. Finally, corneal nerve restoration is now possible with corneal neurotization procedures. SummaryMany novel treatments based on agents that stimulate nerve regrowth are now available to treat NK. Improvement in neurotization procedures could also address advanced stages of this disease with surgery.

show abstract